[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015.Ca Cancer J Clin, 2016, 66:115-132.
[2] Wei D, Miao H, Fang S, et al. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma. Mol Med Rep,2016, 14:1509-1514.
[3] Shibanuma M , Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by tran-sforming growth factor beta 1 and other growth factors. J Biol Chem, 1992, 267:10219-10224.
[4] Choi S J, Moon JH, Ahn YW, et al. Tsc-22 enhances TGF-beta signaling by associating with Smad4 and induces erythroid cell differentiation. J Biol Chem, 2005, 271:23-28.
[5] Ohta S , Yanagihara K , Nagata K . Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by tran-sforming growth factor beta. Biol J, 1997, 324:777.
[6] H?mig-H?lzel C1, van Doorn R, Vogel C, et al. Antagonistic TSC22D1 variants control BRAFE600-induced senescence. Embo Journal, 2014, 30:1753-1765.
[7] Fiol DF, Mak SK, Dietmar Kültz. Specific TSC22 domain transcripts are hypertonically induced and alternatively spliced to protect mouse kidney cells during osmotic stress. FEBS J, 2007, 274:109-124.
[8] Ma L, Chua M S, Andrisani O, et al. Epigenetics in hepa-tocellular carcinoma: an update and future therapy perspectives.世界胃肠病学杂志(英文版), 2014.
[9] Jones P A. Overview of cancer epigenetics. Seminars in Hema-tology, 2005, 42:S3-S8.
[10] Yu Jianhua,Ershler Maxim,Yu Li et al. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.Blood, 2009, 113: 5558-5567.
[11] Nikolaev SI, Sotiriou SK, Pateras IS, et al. A single-nucleo-tide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Research, 2012, 72:6279-6289.
[12] Rodríguez-Colman, Maria J, Schewe M , Meerlo M , et al. Interplay between metabolic identities in the intestinal crypt supports stem cell function. Nature, 2017, 543:424-427.
[13] Qin S, Zhou Y, Chen J, et al. Low levels of TSC22 enhance tumorigenesis by inducing cell proliferation in colorectal cancer. Biochem Biophys Res Commun, 2018, 497.
[14] Guo QS, Song Y, Hua KQ, et al. Involvement of FAK-ERK2 signaling pathway in CKAP2-induced proliferation and motility in cervical carcinoma cell lines. Scientific Reports, 2017, 7:2117.
[15] Cho Min-Ji,Lee Ji-Yeon,Shin Min-Gwan et al. TSC-22 inhibits CSF-1R function and induces apoptosis in cervical cancer. Oncotarget, 2017, 8: 97990-98003.
[16] Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genetics, 2005, 37:265-274.
[17] Kawamata. TSC-22 (TGF-β Stimulated Clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. Curr Cancer Drug Targets,2004 ,4:521-529.
[18] Nakashiro K. Down-regulation of TSC-22 (Transforming growth factor β-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res,1998,58:549-555.
[19] Rentsch CA, Cecchini MG, Schwaninger R, et al. Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancer. Int J Cancer, 2006 ,118:899-906.
[20] Wise TL, Pravtcheva DD. Downregulation of putative tumor suppressor gene TSC-22 in human brain tumors. J Surg Oncol, 2010, 82:57-64.
[21] Jones A, Friedrich K, Rohm M, et al. TSC22D4 is a molecular output of hepatic wasting metabolism. EMBO Mol Med, 2013, 5:294-308.
[22] Hoshida Y, Fuchs BC, Tanabe KK. Genomic risk of hepatitis C-related hepatocellular carcinoma. J Hepatol, 2012, 56:729-730.
[23] Takagi K, Takayama T, Nagase H,et al. High TSC22D3 and low GBP1 expression in the liver is a risk factor for early recurrence of hepatocellular carcinoma. Exp Ther Med, 2011, 2:425-431. |
